Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 1
2019 1
2020 1
2024 1
2025 1
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for hosomi bm
Your search for Mosomi BM retrieved no results
17(S),18(R)-epoxyeicosatetraenoic acid generated by cytochrome P450 BM-3 from Bacillus megaterium inhibits the development of contact hypersensitivity via G-protein-coupled receptor 40-mediated neutrophil suppression.
Saika A, Nagatake T, Kishino S, Park SB, Honda T, Matsumoto N, Shimojou M, Morimoto S, Tiwari P, Node E, Hirata SI, Hosomi K, Kabashima K, Ogawa J, Kunisawa J. Saika A, et al. FASEB Bioadv. 2019 Dec 24;2(1):59-71. doi: 10.1096/fba.2019-00061. eCollection 2020 Jan. FASEB Bioadv. 2019. PMID: 32123857 Free PMC article.
In addition, we found that cytochrome P450 BM-3 derived from Bacillus megaterium stereoselectively converts EPA into 17(S),18(R)-EpETE, which effectively inhibited the development of skin contact hypersensitivity by inhibiting neutrophil migration in a G protein-coupled re …
In addition, we found that cytochrome P450 BM-3 derived from Bacillus megaterium stereoselectively converts EPA into 17(S),18(R)-EpET …
From pixels to pores: 3D-(im)printed hierarchically porous polymer monoliths.
Keitel B, Schimana S, Huber A, Yoshida Y, Shioji H, Furushima Y, Sevinis Ozbulut EB, Ohkawa T, Yoshimoto S, Kubo T, Hosomi H, Kato T, Uehara F, Futamura H, Nakanishi K, Noda A, Yamamoto T, Mizaikoff B, Dinc M. Keitel B, et al. iScience. 2025 Dec 24;29(1):114539. doi: 10.1016/j.isci.2025.114539. eCollection 2026 Jan 16. iScience. 2025. PMID: 41550756 Free PMC article.
Prophylactic cranial irradiation for limited-stage small-cell lung cancer in the modern magnetic resonance imaging era may be omitted: a propensity score-matched analysis.
Ito K, Nakajima Y, Minakami S, Machitori Y, Hosomi Y, Hashimoto K, Saito M, Murofushi KN. Ito K, et al. J Radiat Res. 2024 Dec 3;65(6):805-812. doi: 10.1093/jrr/rrae087. J Radiat Res. 2024. PMID: 39478663 Free PMC article.
The endpoints were the incidence of brain metastasis (BM), neurological causes of death and overall survival (OS). Overall, 80% patients underwent head MRI during the initial staging and 75 patients (no-PCI, n = 50; PCI, n = 25) were matched. ...Although the incidence of B …
The endpoints were the incidence of brain metastasis (BM), neurological causes of death and overall survival (OS). Overall, 80% patie …
Prognostic effects of osteoclast inhibitors in extensive stage small cell lung cancer patients with bone metastases.
Mitsuhashi A, Okuma Y, Zenke Y, Hosomi Y. Mitsuhashi A, et al. Mol Clin Oncol. 2018 Nov;9(5):561-565. doi: 10.3892/mco.2018.1710. Epub 2018 Sep 4. Mol Clin Oncol. 2018. PMID: 30345052 Free PMC article.
Bone metastases (BM) often induce skeletal-related events (SREs) and contribute to poor prognoses in patients with cancer. ...The results of the present study may highlight the possibility that OIs improve the prognosis of ES-SCLC patients with BM....
Bone metastases (BM) often induce skeletal-related events (SREs) and contribute to poor prognoses in patients with cancer. ...The res …
Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Kashima J, Okuma Y, Miwa M, Hosomi Y. Kashima J, et al. Med Oncol. 2016 Nov;33(11):129. doi: 10.1007/s12032-016-0843-8. Epub 2016 Oct 18. Med Oncol. 2016. PMID: 27757781 Clinical Trial.
There is no consensus about which EGFR tyrosine kinase inhibitor (TKI) is most effective against BM in such patients. Here, we compared prognoses of patients with EGFR-TKI naive EGFR-positive BM treated with erlotinib or gefitinib after BM diagnosis. ...We us …
There is no consensus about which EGFR tyrosine kinase inhibitor (TKI) is most effective against BM in such patients. Here, we compar …